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Abstract   48 
 49 
Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR) are two of the 50 
most common and severe causes of vision loss in the population.  Both conditions are associated 51 
with excessive levels of vascular endothelial growth factor (VEGF) in the eye which results in an 52 
increase in the formation of new blood vessels through a process called neovascularisation. As such, 53 
anti-VEGF therapies are currently utilised as a treatment for patients with AMD  however they are 54 
associated with painful administration of injections and potential degeneration of healthy 55 
endothelium.  There is therefore growing interest in alternate treatment options to reduce 56 
neovascularisation in the eye. The use of carotenoids, lutein (L) and zeaxanthin (Z), has been shown 57 
to improve vision loss parameters in patients with AMD, however the underlying mechanisms are 58 
not well-understood.  We studied the impact of these compounds on neovascularisation processes 59 
using an in vitro cell model of the retinal microvascular endothelium. Our findings show that L and Z 60 
reduced VEGF-induced tube formation whilst, in combination (5:1 ratio), the compounds 61 
significantly blocked VEGF-induced neovascularisation.  The carotenoids, individually and in 62 
combination, reduced VEGF-induced oxidative stress concomitant with increased activity of the 63 
NADPH oxidase, Nox4.  We further demonstrated that the Nox4 inhibitor, GLX7013114, attenuated 64 
the protective effect of L and Z. Taken together, these findings indicate the protective effect of the 65 
carotenoids, L and Z, in reducing VEGF-mediated neovascularisation via a Nox4-dependent pathway.  66 
These studies implicate the potential for these compounds to be used as a therapeutic approach for 67 
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Age-related macular degeneration (AMD) is a leading cause of vision loss in the ageing population 94 
(Bourne et al. 2014).  The pathogenesis of AMD is multifactorial with a variety of associated factors 95 
including age, genetic contribution and environmental stress.  The clinical hallmark of dry AMD is the 96 
appearance of localised deposits of oxidised lipids and proteins within the eye, known as drusen, 97 
which form between the basement membrane and Bruch’s membrane (Gorusupudi et al. 2017).  The 98 
most devastating hallmark of AMD is seen in patients with the wet-form of the disease in which 99 
neovascularisation occurs resulting in sudden and irreversible loss of vision with intra-vitreal 100 
injections the treatment option  (Ferris et al. 1984).   101 
 102 
Severe cases of diabetic retinopathy (DR) can also lead to neovascularisation (in proliferative DR) 103 
leading to irreversible loss of vision (He, M. S. et al. 2018, Topouzis et al. 2009).   Worldwide, there 104 
were an estimated 425 million people suffering with diabetes in 2017 which is projected to reach 105 
629 million in 2045 (Ogurtsova et al. 2017). DR is a serious complication in chronic, poorly-controlled 106 
diabetes (National Eye Institute) and a leading cause of vision impairment and loss in the working 107 
population (Porta and Bandello. 2002).  The prevalence of vision-threatening proliferative DR which 108 
can lead to blindness is 6.32% in Europe and 7.26% worldwide (Teo et al. 2020).   109 
 110 
DR is a complex, multifactorial disease which progresses from a mild, non-proliferative condition, 111 
characterised by breakdown of the retinal microvasculature, pericyte loss and capillary 112 
degeneration, to a proliferative form of the disease which is associated with new blood vessel 113 
formation (Fong et al. 2003, Wong et al. 2016).  This neovascularisation can bleed and cause 114 
mechanical traction and result in retinal detachment and subsequent blindness (Stitt et al. 2013).  115 
Prolonged hyperglycaemia in diabetic patients results in metabolic disruption within the retina, with 116 
the release of a number of growth, neurotrophic and inflammatory factors (Ola et al. 2012, Qian and 117 
Ripps. 2011, Tarr et al. 2013).  Many of these released molecules result in vascular disruption due to 118 
the key pathogenic factor released in DR, vascular endothelial growth factor (VEGF).   Hypoxia which 119 
is observed in patients with proliferative DR, elevates VEGF levels, to result in increased migration 120 
and proliferation of retinal endothelial cells to form new blood vessels (Simo et al. 2006). 121 
Hyperglycaemia-induced oxidative stress in the microvasculature is therefore a key pathology 122 
related to the development of DR. As such, excessive reactive oxidative stress (ROS) accumulation 123 
occurs in the retina of diabetic patients (Calderon et al. 2017, He, M. et al. 2013, Tan, J. S. et al. 124 
2008).  Cytosolic NADPH oxidases, Nox, are the primary enzyme family which is responsible for 125 
generating cellular ROS by catalysing the reduction of molecular oxygen to the superoxide anion via 126 
oxidising NADPH to NADP.  Whilst there are three Nox isoforms found in the retina (Nox1, Nox2, 127 
Nox4), Nox4 is the predominant isoform (Serrander et al. 2007) and has been closely linked with the 128 
development and severity of DR in type 2 diabetic patients (Appukuttan et al. 2018, Ibrahim et al. 129 
2015, Kim et al. 2012, Kowluru et al. 2014, Li et al. 2010, Meng et al. 2018, Wang et al. 2014).  130 
Indeed, Nox4 activity is associated with endothelial cell processes linked to retinopathy including 131 
permeability, hyper-proliferation and tubulogenesis (Li et al. 2010). The inhibition of Nox4 therefore 132 
represents a potential therapeutic mechanism to target various microvascular complications seen in 133 
retinopathy.   134 
 135 
For proliferative DR, panretinal photocoagulation therapy has been the gold standard for treatment 136 
of DR to prevent severe vision loss. The therapy is, however, inherently a destructive therapy 137 
resulting in potential loss of photoreceptors, and therefore loss of peripheral field and night vision 138 
(Sun, J. K. et al. 2019), as well as vitreal haemorrhage (Coney. 2019).  Anti-VEGF treatments, such as 139 
the full-length recombinant humanized anti-VEGF monoclonal antibody Bevacizumab (Avastin) 140 
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(Ferrara et al. 2004) and the recombinant antibody fragment of humanised anti-VEGF monoclonal 141 
antibody Ranibizumab (Lucentis) (Heier et al. 2006), have been recently been advocated as 142 
alternative therapies which have been successful in diabetic and AMD clinics.  These are 143 
administered as intravital injections and can therefore be painful for patients and associated with a 144 
range of potential complications including cataract, infectious endophthalmitis, conjunctival 145 
haemorrhage and retinal detachment (Coney. 2019).   146 
 147 
There is therefore a growing need to understand the development of novel therapeutic agents to 148 
inhibit VEGF activity and thus reduce retinal injury and improve vision outcomes for patients with 149 
diabetes and AMD.  Whilst different vascular beds undergo neovascularisation in each disease, 150 
retinal endothelium for DR and choroidal endothelium for AMD, finding therapeutic interventions 151 
for DR are also likely to have a positive effect on the incidence of irreversible loss of vision.  It is 152 
therefore vital to understand the molecular mechanisms which underlie neovascularisation in DR 153 
pathology,  and use this information to develop therapeutic options for patients. 154 
 155 
We have previously identified the presence of novel GPCRs, T1R2/3, in human retinal microvascular 156 
endothelial cells, which are activated by a range of acutely sweet molecules (Lizunkova et al. 2019). 157 
Our studies demonstrated that the sweetener, sucralose, blocked VEGF-induced angiogenic 158 
processes such as permeability and neovascularisation, in the human retinal microvasculature.  159 
These studies indicate the potential link between dietary components and improved outcomes for 160 
patients with neovascularisation and pave the way for new techniques to tackle the condition. 161 
Indeed, recent clinical studies have investigated the potential for a range of dietary components, 162 
including micronutrients and vitamins, to reduce various aspects of retinopathy pathology including 163 
age-related macular degeneration (Chew et al. 2013, Dow et al. 2018, Kowluru, Kanwar et al. 2008, 164 
Lee et al. 2010).  Of these, two of the most extensively studied are lutein (L) and zeaxanthin (Z). 165 
These xanthophyll carotenoids are endogenously expressed at high levels in the retina however 166 
there is no de novo synthesis of either therefore dietary consumption of these molecules is 167 
important for vision (Scripsema et al. 2015).  Indeed, in a range of clinical studies, such as CARMIS, 168 
LUTEGA and AREDS2, L and Z at different ratios have been shown to protect against markers of 169 
retinopathy in AMD (Chew et al. 2013, Dawczynski et al. 2013, Piermarocchi et al. 2012). In the Blue 170 
Mountain Study, supplementation of L and Z is associated with as much as 65% reduced risk of 171 
neovascular AMD (Tan, J. S. et al. 2008).  There are, however, limited studies which assess L and Z 172 
supplementation in DR or the molecular mechanisms through which these micronutrients impact 173 
the endothelium. In vivo studies indicated that L and Z act as antioxidants to preserve retinal 174 
function and prevent neuronal loss in the retina of diabetic models (Arnal et al. 2009, Kowluru, 175 
Menon et al. 2008, Miranda et al. 2006, Sasaki et al. 2010). In humans, Hu et al demonstrated that L 176 
and Z supplementation in patients with non-proliferative DR resulting in improved visual function as 177 
assessed by visual acuity, contrast sensitivity and macular pigment optical density (Hu et al. 2011).  178 
Whilst L and Z are found in different foods such as spinach, corn and eggs, many studies have tested 179 
commercially-available supplements, including Macushield which comprises of a 5:1 ratio of L to Z, in 180 
patients with AMD (Akuffo et al. 2015, Al-Ahmary. 2010, Crosby-Nwaobi et al. 2016).  Despite these 181 
studies, there is limited understanding of the effect of L and Z at a cellular level in the retina and 182 
specifically how these compounds could be efficacious in reducing retinal neovascularisation, 183 
associated with DR.   184 
 185 
We have therefore sought to address this using physiologically-relevant concentrations of L and Z, or 186 
combination treatment (5:1 lut:zeax), in human retinal microvascular endothelial cells. We utilised 187 
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VEGF as an in vitro model of DR  and the anti-VEGF Bevacizumab as a positive control for currently 188 
available pharmaceutical therapy.  189 
 190 
Human retinal microvascular endothelial cells (RMVEC) were purchased from Cell Systems (Kirkland, 191 
WA) and cultured specialised supplemented vascular cell media using culture boost. Cells were 192 
utilised between passages 2 and 7 only and routinely checked for endothelial cell characteristics 193 
including vascular endothelial cadherin expression and uptake of acetylated LDL.  Unless otherwise 194 
stated, all reagents were sourced from Sigma-Aldrich. 195 
 196 
Cell viability was assessed using 3-4,5-dimethylthiazole-2-yl-2,5-diphenyltetrazolium bromide (MTT). 197 
RMVEC were exposed to bevacizumab, L, Z or 5:1 lut:zeax, or vehicle (H2O), treatment at a range of 198 
concentrations (0.05, 0.075. 0.1, 0.25, 0.5, 1 µg/µl) for 24 h, followed by incubation with MTT 199 
reagent for 2 h at 37
o
C.  Absorbance was assessed at 570 nm using a microplate reader (Victor 200 
Perkin-Elmer) and viability was calculated as % normalised to vehicle.   Cellular ROS was assessed 201 
using the fluorogenic dye 2',7'–dichlorofluorescin diacetate (DCFDA).  RMVEC were exposed to 202 
DCFDA (10 µM) for 30 min at 37
o
C and then replaced with bevacizumab, L, Z, or 5:1 lut:zeax with 203 
VEGF (50 ng/ml) or vehicle (H2O).  DCFDA fluorescence was measured at 488 nm using a fluorescent 204 
plate reader (Victor, Perkin Elmer) for time points from 10 to 240 mins.   205 
 206 
Cellular glutathione (GSH) and Nox4 activity were quantified using commercially-available kits.  For 207 
all kits, RMVEC were plated in a 96-well plate and exposed to bevacizumab, L, Z or 5:1 lut:zeax in the 208 
presence and absence of VEGF (50 ng/ml), for 24 h.  For the GSH Bioxytech activity kit (Merck 209 
Millipore, Hertfordshire, UK), levels of the monochlorobimane dye bound to reduced or oxidised 210 
glutathione were quantified by fluorescence measured at an excitation and emission of 380/461nm 211 
using a fluorescent plate reader (Victor, Perkin Elmer).  For the Nox4 activity kit (Cusabio, Texas, 212 
USA), the assay was performed as per the manufacturer’s protocol and absorbance was measured at 213 
450nm using a microplate reader (Tecan Sunrise).   214 
 215 
Angiogenic processes were measured as cell proliferation, migration, adhesion and 216 
neovascularisation as previously described (Lizunkova et al. 2019).  In brief, RMVEC were quiesced 217 
for 24 h with 1% FBS followed by exposure to bevacizumab, L, Z or combined treatment, in the 218 
presence and absence of VEGF, for 6 h. Alternatively, cells were exposed to bevacizumab, L, Z or 219 
combined treatment, with VEGF (50 ng/ml), in the presence of GLX7013114 (1 µM) (Raystar Bio, 220 
Hangzhou Guangyuan, China) or the vehicle control (DMSO).  To ensure that bevacizumab did not 221 
neutralise VEGF in preparation, VEGF treatment was administered separately but within a 5 minute 222 
window. Cells were then counted using a haemocytometer for the cell proliferation assay.  For cell 223 
migration assay, RMVEC were plated for 24 h, followed by a scratch using a pipette tip and 224 
immediately expose to bevacizumab, L, Z or 5:1 lut:zeax, in the presence and absence of VEGF (50 225 
ng/ml).  Migration was then monitored at 2 h time intervals and images were captured at × 10 226 
magnification using a Zoe™ Cell Imager (BioRad).  Cell migration was assessed using the MiToBo 227 
analyser software in Image J as previously described (Lizunkova et al. 2019).  Cell adhesion was 228 
assessed following exposure to bevacizumab, L, Z or 5:1 lut:zeax, in the presence and absence of 229 
VEGF (50 ng/ml), for 2 h. RMVEC were then rinsed and MTT assay was performed as for the viability 230 
assay to quantify adhered cells.  Neovascularisation was measured by plating cells onto Matrigel
TM
-231 
coated plasticware (BD Biosciences, Oxford, UK) and immediately exposing cells to bevacizumab, L, Z 232 
or 5:1 lut:zeax, in the presence and absence of VEGF (50 ng/ml), for 6 h. Alternatively, RMVEC were 233 
exposed to bevacizumab, L, Z or 5:1 lut:zeax, with VEGF (50 ng/ml), in the presence and absence of 234 
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GLX7013114 (1 µM). Images of tube formation were captured at × 10 magnification using a Zoe™ 235 
Cell Imager (BioRad). The number of joints and mesh size were calculated by using the Angiogenesis 236 
Analyser software in Image J as previously described (Lizunkova et al. 2019).  237 
 238 
The experimental number is presented in the legend for each experiment and an average from two 239 
wells was assessed to represent an n of 1. Variance was assessed by using Bartlett’s test. For data 240 
sets not reaching significance (Figures 1A-C, 2A,C,E, F) the Kruskal-Wallis test was used followed by 241 
Dunn’s test. For all other data sets, differences among the means were tested for significance in all 242 
experiments by ANOVA with Tukey’s range significance difference test. Significance was reached 243 
when p < 0.05. Values are presented as mean ± standard error mean (S.E.M.). 244 
 245 
To understand the role of L, Z or the combined treatment of L:Z at a 5:1 ratio, compared to 246 
bevacizumab as a current therapy, we first sought to assess the cytotoxic effect of each treatment at 247 
a range of concentrations from 0.05 to 1 µg/µl.  Whilst there was a trend for deceased viability at 248 
the highest concentration of L, Z, or 5:1 lut:zeax treatment (1 µg/µl), this did not reach significance 249 
(Figure 1A).  In contrast, bevacizumab, the anti-VEGF antibody, resulted in a significant decrease in 250 
cell viability at 0.5 and 1 µg/µl to 62.2 ± 3.9% and 51.9 ± 3.3% (Figure 1A). Further studies for L, Z, 5:1 251 
lut:zeax treatment and bevacizumab were performed at a non-cytotoxic but effective concentration 252 
of 0.25 µg/µl where there was no significant difference in viability between any of the treatment 253 
groups (Avery et al. 2006, Sonmez et al. 2008, Wang et al. 2014).  We next studied the effect of 254 
these compounds on the ability of RMVEC to undergo VEGF-induced angiogenic processes.  In the 255 
absence of VEGF, bevacizumab, L, Z and 5:1 lut:zeax treatment had no impact on cell proliferation 256 
(Figure 1B), adhesion (Figure 1C), migration (Figure 1D) and neovascularisation as measured by 257 
angiogenic potential (number of joints) and mesh size (Figure 1E-G).  As anticipated, VEGF exposure 258 
significantly increased all of these measurements (Figure 1B-F) (Lizunkova et al. 2019).  Interestingly, 259 
treatment with L or Z significantly reduced all of the VEGF-induced angiogenic processes studied, 260 
however these protective effects did not return values to those seen in vehicle-treated RMVEC 261 
(Figure 1B-G).  In contrast, VEGF-induced increases in cell proliferation, adhesion, migration and 262 
mesh size were effectively blocked by exposure to either bevacizumab or 5:1 lut:zeax treatment 263 
(Figure 1B, C, D, G). Taken together, these findings show that independent treatment of L or Z can 264 
reduce VEGF-induced angiogenic processes in cells from the human retinal microvasculature. More 265 
importantly, these findings show that combination 5:1 lut:zeax treatment is highly effective in 266 
attenuating vascularisation in the retina, similar to a primary treatment for DR, bevacizumab. 267 
 268 
One of the key clinical features of DR is oxidative stress associated with the increased inflammation 269 
and retinal injury (Calderon et al. 2017, He, M. et al. 2013, Tan, S. M. et al. 2013).  Therefore to 270 
further understand the mechanism through which L and Z, and the combination treatment, protect 271 
against VEGF-induced angiogenic processes in human retinal microvascular endothelial cells, the 272 
next studies performed were to assess oxidative stress.  As anticipated, exposure to VEGF 273 
significantly increased ROS accumulation in RMVEC over the 2 h period (Figure 2A). Interestingly, 274 
treatment with L, Z, 5:1 lut:zeax treatment or bevacizumab had no impact on cellular ROS levels 275 
(Figure 2A).  Following exposure to both VEGF and the therapeutic treatments, L and Z significantly 276 
reduced, but did not block, VEGF-induced ROS accumulation in RMVEC (Figure 2B). In contrast, 277 
bevacizumab and 5:1 lut:zeax treatment effectively attenuated VEGF-induced cellular ROS to return 278 
levels to those seen in vehicle-treated RMVEC (Figure 2B).  Levels of the endogenous antioxidant 279 
enzyme, glutathione (GSH), were measured as the primary protein responsible for clearing excess 280 
ROS and preventing oxidative stress. The observed VEGF-induced decrease in GSH expression was 281 
7 
 
significantly attenuated by exposure to bevacizumab and 5:1 lut:zeax treatment (Figure 2C). Whilst 282 
independent treatment with L also exerted a protective effect, to a lesser degree than combined 283 
treatment, Z exposure had no impact on cellular GSH expression (Figure 2C). These data 284 
demonstrate a clear role for 5:1 lut:zeax treatment in reducing VEGF-mediated oxidative stress in 285 
human retinal microvascular endothelial cells. 286 
 287 
Nox4 is a major NADPH oxidase enzyme found in the retinal microvasculature and the only 288 
constitutively active Nox isoform (Serrander et al. 2007).  In addition, Nox4 has been demonstrated 289 
to play a significant role in the development of retinal injury seen in DR (Appukuttan et al. 2018, Li et 290 
al. 2010, Wang et al. 2014). Therefore we next studied the effect of the potential therapeutic 291 
carotenoids on Nox4 activity. Exposure to bevacizumab, L, Z or 5:1 lut:zeax had no effect on Nox4 292 
activity whereas exposure to VEGF alone significantly increased Nox4 activity (Figure 2D). 293 
Interestingly, all 4 therapeutic compounds significantly reduced VEGF-induced Nox4 activity but 294 
were unable to completely attenuate the effect (Figure 2D).  To understand whether the reduction 295 
in VEGF-mediated Nox4 activity was associated with the protective effect of L, Z or 5:1 lut:zeax, the 296 
final experiments utilised the specific Nox4 inhibitor, GLX7013114.  RMVEC were exposed to VEGF in 297 
the presence of either bevacizumab, L, Z or 5:1 lut:zeax treatment, and with or without GLX7013114.  298 
Cell proliferation and mesh size in Matrigel
TM
 were assessed as markers for neovascularisation. 299 
Whilst the Nox4 inhibitor had no effect on cell proliferation or mesh size at baseline, following VEGF 300 
exposure, GLX7013114 significantly reduced, but not blocked, VEGF-induced angiogenic processes 301 
(Figure 2E and F).  The protective effect of bevacizumab, in protecting against VEGF-induced 302 
proliferation and mesh formation, was not affected by Nox4 inhibition indicative of a Nox4-303 
independent signal (Figure 2E and F).  Interestingly, Nox4 inhibition significantly blocked the 304 
protective effect of L, Z and 5:1 lut:zeax treatment and prevented each from reversing VEGF-induced 305 
neovascularisation (Figure 2E and F). Taken together, these findings demonstrate that L, Z and 5:1 306 
lut:zeax therapy may act as antioxidants, in VEGF-treated cells, to reduce angiogenic processes in a 307 
Nox4-dependent manner.  308 
 309 
In the present study, we demonstrate the effect of the carotenoids L and Z, independently and in 310 
combination, on neovascularisation processes in human retinal microvascular endothelial cells. Our 311 
findings show that, in a VEGF-induced in vitro model of the eye linked to DR, both L and Z attenuate 312 
the neovascularisation processes of proliferation, adhesion, migration and tube formation similar to 313 
a current retinopathy therapy, bevacizumab.  Interestingly, a combination therapy of L and Z (5:1 314 
ratio) which mimics commercially-available supplements, such as Macushield (Akuffo et al. 2015, 315 
Crosby-Nwaobi et al. 2016), is more effective in blunting VEGF-mediated neovascularisation than 316 
independent treatment with each carotenoid.  Furthermore, L and Z treatment, independently or in 317 
combination, blocked VEGF-mediated oxidative stress and Nox4 activity. Finally, we demonstrate 318 
that Nox4 activation is able to reverse the protective effect of the carotenoids on endothelial cell 319 
proliferation and tube formation. Taken together, these data show that L and Z can exert Nox4-320 
dependent antioxidant effects which attenuate VEGF-induced neovascularisation.  This study 321 
provides evidence that L and Z attenuate neovascularisation in an in vitro model of retinal injury 322 
linked to retinopathy. Findings demonstrate the role that Nox4 plays in regulating this protective 323 
effect of carotenoids and identifies a novel molecular target in the treatment of patients with 324 
retinopathy. 325 
 326 
Patients who display retinal neovascularisation, for example, those with diabetic macular oedema in 327 
DR will be treated using intravital injection of anti-VEGF treatments (Ferrara et al. 2004, Heier et al. 328 
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2006).  In the present study, we utilised one such treatment, a full-length anti-VEGF monoclonal 329 
antibody called bevacizumab, as a therapeutic comparison to lutein and zeaxanthin 330 
supplementation.  Bevacizumab has been demonstrated to be effective in causing endothelial cell 331 
apoptosis which results in a loss of vascular endothelium within neovascular membranes and 332 
regression of abnormal neovascularisation in the retina of diabetic patients (Ababneh et al. 2013, 333 
Han et al. 2012).  In vitro studies demonstrate that bevacizumab decreases VEGF-induced tube 334 
formation in retinal endothelial cells (Palanisamy et al. 2019).  Our studies demonstrate that 335 
exposure of human retinal microvascular endothelial cells to varying concentrations of bevacizumab, 336 
in the absence of VEGF, causes cell death at concentrations of 0.5 and 1 µg/µl. In contrast, L, Z, or 337 
combination treatment had no impact on cell viability at baseline conditions indicating that these 338 
carotenoids may offer a less toxic approach than current anti-VEGF therapy.  At present, a small 339 
percentage of patients receiving conventional anti-VEGF therapy can suffer from complications 340 
associated with neurodegeneration of healthy vessels and retinal detachment (Coney. 2019).  In 341 
work presented here, we show that L, Z or 5:1 lut:zeax treatment have no impact on 342 
neovascularisation processes – proliferation, adhesion, migration and tube formation – in the 343 
absence of VEGF.  These studies indicate that L and Z are working through a mechanism which blocks 344 
VEGF, and that healthy vasculature is not be affected by exposure to these carotenoids, either 345 
independently or in combination. Therefore L and Z may represent a therapeutic approach which 346 
could be preferable to other current anti-VEGF therapies.  Whilst the human cell line model of 347 
retinopathy is a great tool to establish molecular mechanisms related to DR, further studies are 348 
essential to establish the role of L and Z in a physiological setting using in vivo techniques. Such 349 
studies include the use of microscopy with retinal whole mounts stained for endothelial cells using 350 
the WBN/Kob genetic or hypoxia inducible mouse models which display capillary occlusion, retinal 351 
ischaemia and neovascularisation characteristics of the disease (Olivares et al. 2017, Sun, Q. et al. 352 
2020).  Such studies would demonstrate the protective effect of L and Z combination treatment in 353 
vivo and link closely to the clinical studies with these micronutrients.  354 
  355 
There have been several clinical studies which implicate a variety of dietary components in 356 
improving visual acuity in settings of AMD.  These studies, such as the Blue Mountain Study, CARMIS 357 
and AREDS2, show that dietary supplementation with L and Z, amongst other micronutrients, reduce 358 
the risk of developing neovascular AMD (Chew et al. 2013, Dawczynski et al. 2013, Piermarocchi et 359 
al. 2012, Tan, J. S. et al. 2008).  Despite these findings, there are limited studies which assess this 360 
efficacy or the protective mechanisms at a vascular level in these patients (Hu et al. 2011).  Our 361 
findings demonstrate a protective, but not ablating, effect of either L or Z in settings of VEGF-362 
mediated neovascularisation.  Interestingly, when administered as a combination therapy, at 5:1 363 
lut:zeax ratio, complete attenuation of VEGF-induced neovascular processes was observed. This 364 
indicates a therapeutic effect of this ratio of L and Z which is enhanced when administered in 365 
combination which is not surprising given that commercially-available supplements such as 366 
Macushield, are comprised of 5:1 ratio of L to Z (Akuffo et al. 2015, Crosby-Nwaobi et al. 2016).  367 
Bioavailability data indicates that there is a significant increase in plasma L (from 0.372 to 3.163 368 
µg/dL) and Z (0.117 to 0.391 µg/dL) concentrations,  following 12 week administration of 5:1 ratio of 369 
supplement (Juturu, et al. 2015).  Of this large increase in carotenoid concentration, ocular tissues 370 
including the retina contain around 100-fold higher levels of L and Z compared to other tissues 371 
(Handelman et al. 1988, Landrum et al. 1997).  These values correspond to around 0.25 µg/µl L and 372 
0.048 µg/µl Z in the retina following 5:1 lut:zeax supplementation et al. 2015 ).  In the present study, 373 
we used a concentration of 0.25 µg/µl for L, Z and the combination therapy, based on cytotoxicity 374 
study using a current anti-VEGF therapy, bevacizumab, which was used as a therapeutic comparison.  375 
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This converts to a concentration of 0.042 µg/µl Z and 0.208 µg/µl L which is physiologically-relevant 376 
for the retina following supplementation. Findings from this study can therefore be linked to 377 
supplementation studies which confer that L:Z, administered in combination at a 5:1 ratio, are 378 
protective against VEGF-induced neovascularisation processes.  379 
 380 
The pathology of neovascularisation in the eye is generally linked with hyperglycaemia-induced 381 
oxidative stress. As such, micronutrients and vitamins which exert an antioxidant effect, in reducing 382 
oxidative stress in the retina, represent a potential therapeutic approach.  Whilst association studies 383 
link dietary vitamin C and E with reduced markers of DR, multi-oxidant clinical trials show no 384 
significant improvement of the disease (Tabatabaei-Malazy et al. 2019).  In the present study, we 385 
demonstrate the antioxidant properties of L, Z and combination therapy, in retinal microvascular 386 
endothelial cells, in settings of VEGF-induced oxidative stress.  This is the first study performed in the 387 
retinal endothelium to show this effect however findings are in keeping with in vitro studies in the 388 
retinal pigment epithelium.  Here, L has been shown to activate nuclear translocation of Nrf2 to 389 
reduce high glucose- or hypoxia-induced oxidative stress (Gong et al. 2017, Shivarudrappa and 390 
Ponesakki. 2019).  In the choroidal vasculature, L supplementation, alongside consumption of long-391 
chain polyunsaturated fatty acids, is associated with reduced Nox4-mediated oxidative stress (Yanai 392 
et al. 2018).  Interestingly, Nox4 is the predominant Nox enzyme found in the retina, and has been 393 
linked to the onset of DR (Appukuttan et al. 2018, Li et al. 2010, Wang et al. 2014).  In the present 394 
study, we demonstrate that L, Z and combination treatment lower ROS accumulation and Nox4 395 
activity. Using the Nox4 inhibitor (GLX7013114), we further show that carotenoid-mediated 396 
protection against neovascularisation, in settings of VEGF, is dependent on Nox4 activity. This is in 397 
contrast to bevacizumab, where the protective effect of the humanised antibody on VEGF-mediated 398 
neovascularisation is unaffected by Nox4 activation.  These findings represent a key difference 399 
between L and Z therapeutic approach and the typical anti-VEGF therapies used routinely.  400 
Furthermore, these studies indicate Nox4 as a key therapeutic target to treat the excessive retinal 401 
vascularisation seen in patients with DR.  It is worth noting, however, that there are other Nox 402 
isoforms present within the retina which may play a role in regulating neovascularisation, such as 403 
Nox1 and Nox2 (Serrander et al. 2007). Indeed, in prostate cancers, Nox1 has been shown to trigger 404 
the angiogenesis switch whilst Nox2-derived ROS has been identified to mediate VEGF-induced 405 
migration (Arbiser et al. 2002, Ushio-Fukai et al. 1996).  Therefore, further studies are needed to 406 
establish whether other Nox isoforms are mediated by L and Z to attenuate VEGF-induced 407 
neovascularisation and impact retinopathy. 408 
 409 
Taken together, the present studies utilise a well-established in vitro model of retinopathy, and 410 
mirror findings from clinical studies such as AREDS2.  Further work is, however, needed to establish 411 
the mechanism through which L and Z regulate Nox4 activity and understand how this can be 412 
translated to a more robust therapeutic approach for patients with DR.  413 
 414 
Figure legends 415 
Figure 1: Lutein and zeaxanthin protect against VEGF-induced angiogenic processes in human 416 
retinal microvascular endothelial cells. Endothelial cells were exposed to Bevacizumab, Lutein, 417 
Zeaxanthin, or a combination of lutein and zeaxanthin (5:1 lut:zeax), in the presence (closed bars) 418 
and absence (open bars) of VEGF (50 ng/ml). Cell viability (A), proliferation (B), and adhesion (C) 419 
were measured by MTT assay and cell count. Cell migration (D) was assessed by scratch assay, and 420 
neovascularisation (E, F and G) was measured using Matrigel
TM
 assay. Representative images of 421 
Matrigel
TM
 assay were captured in the presence and absence of VEGF (E) and quantification was 422 
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performed (F and G). Images were captured at x20 magnification, scale bar 200 µm. n=5, *p<0.05 423 
versus 0 µg/µl (A) or vehicle (H2O) (B-F), 
#
p<0.05 versus VEGF.  424 
 425 
Figure 2: Lutein and zeaxanthin reduce VEGF-induced oxidative stress and Nox4 activity to 426 
attenuate angiogenic processes. Panels A-D: Endothelial cells were exposed to Bevacizumab, Lutein, 427 
Zeaxanthin, or a combination of lutein and zeaxanthin (5:1 lut:zeax), in the presence (closed bars) 428 
and absence (open bars) of VEGF (50 ng/ml).  ROS production (A and B), GSH expression (C) and 429 
Nox4 activity (D) were assessed using DCFDA, monochlorobimane dye, and specific ELISA kit 430 
respectively. Panels E and F: Endothelial cells were exposed to Bevacizumab, VEGF, Lutein, 431 
Zeaxanthin, or a combination of lutein and zeaxanthin (5:1 lut:zeax), in the presence (closed bars) 432 
and absence (open bars) of the Nox4 inhibitor, GLX7013114 (1 µM) or the vehicle (DMSO). Cell 433 
proliferation (E) and neovascularisation (F) were measured using cell count and Matrigel
TM
 assay 434 
respectively. n=5, *p<0.05 versus vehicle for VEGF (H2O), 
#
p<0.05 versus VEGF, or 
δ
p<0.05 versus 435 
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